Brimonidine for glaucoma

Expert Opinion on Drug Safety

Volumn 9, Issue 3, 2010, Pages 483-491

  Rahman, Mamun Q ^a   Ramaesh, Kanna ^a   Montgomery, Donald M ^b  

^a GARTNAVEL GENERAL HOSPITAL   (United Kingdom)

^b GLASGOW ROYAL INFIRMARY   (United Kingdom)

Author keywords

2 adrenoceptor agonist; Brimonidine; Combigan; Glaucoma; Neuroprotection

Indexed keywords

ADRENALIN; ALPHA 1 ADRENERGIC RECEPTOR; ALPHA 2 ADRENERGIC RECEPTOR; APRACLONIDINE; BASIC FIBROBLAST GROWTH FACTOR; BENZALKONIUM CHLORIDE; BETAXOLOL; BIMATOPROST; BRIMONIDINE; BRIMONIDINE PLUS TIMOLOL; BRINZOLAMIDE; CARBONATE DEHYDRATASE INHIBITOR; CHLORINE DIOXIDE; CLONIDINE; DIPIVEFRINE; DORZOLAMIDE; DORZOLAMIDE PLUS TIMOLOL; ECOTHIOPATE IODIDE; LATANOPROST; MELANIN; PHYSOSTIGMINE; PILOCARPINE; POLITEF; PURITE; TIMOLOL; TIMOLOL MALEATE; TRAVOPROST; UNCLASSIFIED DRUG;

AQUEOUS HUMOR; BLEPHARITIS; BLEPHAROCONJUNCTIVITIS; CENTRAL NERVOUS SYSTEM DEPRESSION; CHRONOTROPISM; CILIARY BODY; CLINICAL PRACTICE; CLINICAL TRIAL; CONJUNCTIVAL HYPEREMIA; CONJUNCTIVITIS; DEPRESSION; DOSE RESPONSE; DRUG ABSORPTION; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG METABOLISM; DRUG RETENTION; DRUG SAFETY; DRUG TOLERABILITY; DRUG USE; DRUG WITHDRAWAL; EYE BURNING; EYE DISCOMFORT; FOLLICULAR CONJUNCTIVITIS; GLAUCOMA; HUMAN; HYPERPOLARIZATION; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; LASER COAGULATION; LIVER FAILURE; LIVER METABOLISM; MONOTHERAPY; NEUROPROTECTION; OPEN ANGLE GLAUCOMA; PREGNANCY; PRESCRIPTION; QUALITY OF LIFE; REVIEW; SIDE EFFECT; TASTE; TRABECULECTOMY; TRABECULOPLASTY; UNSPECIFIED SIDE EFFECT; VASOCONSTRICTION;

ADRENERGIC ALPHA-AGONISTS; ANIMALS; ANTIHYPERTENSIVE AGENTS; GLAUCOMA; HUMANS; INTRAOCULAR PRESSURE; QUINOXALINES;

EID: 77951626924     PISSN: 14740338     EISSN: None     Source Type: Journal    
DOI: 10.1517/14740331003709736     Document Type: Review

References (80)

1. Read RM, Spaeth GL. The practical clinical appraisal of the optic disc in glaucoma: the natural history of cup progression and some specific disc-field correlations. Trans Am Acad Ophthalmol Otolaryngol 1974;78(2):OP255-74
2. Quigley HA. Number of people with glaucoma worldwide. Br J Ophthalmol 1996;80(5):389-393
3. Sommer A. Intraocular pressure and glaucoma. Am J Ophthalmol 1989;107(2):186-188
4. Bengtsson B, Heijl A. A long-term prospective study of risk factors for glaucomatous visual field loss in patients with ocular hypertension. J Glaucoma 2005;14(2):135-138 (Pubitemid 40389182)
5. Cillino S, Zeppa L, Di Pace F, et al. E-PTFE (Gore-Tex) implant with or without low-dosage mitomycin-C as an adjuvant in penetrating glaucoma surgery: 2 year randomized clinical trial. Acta Ophthalmol 2008;86(3):314-321
6. Papaconstantinou D, Georgalas I, Karmiris E, et al. Trabeculectomy with OloGen versus trabeculectomy for the treatment of glaucoma: a pilot study. Acta Ophthalmol 2010;88:80-85
7. Minckler DS, Hill RA. Use of novel devices for control of intraocular pressure. Exp Eye Res 2009;88(4):792-798
8. Rosin A. Pilocarpine. A miotic of choice in the treatment of glaucoma has passed 110 years of use. Oftalmologia 1991;35(1):53-55
9. Snell S. On eserine and pilocarpine in glaucoma and esserine in ocular neuralgia. British Medical Association, London; 1882
10. Leopold IH, Gold P, Gold D. Use of a thiophosphinyl quaternary compound (217-MI) in treatment of glaucoma. AMA Arch Ophthalmol 1957;58(3):363-366
11. Barker WB. Abstracts-glaucoma. Br J Ophthalmol 1927;11:237-252
12. Podos SM, Ritch R. Epinephrine as the initial therapy in selected cases of ocular hypertension. Surv Ophthalmol 1980;25(3):188-194
13. Mandell AI, Stentz F, Kitabchi AE. Dipivalyl epinephrine: a new pro-drug in the treatment of glaucoma. Ophthalmology 1978;85(3):268-275
14. Kass MA, Mandell AI, Goldberg I, et al. Dipivefrin and epinephrine treatment of elevated intraocular pressure: a comparative study. Arch Ophthalmol 1979;97(10):1865-1866
15. Kohn AN, Moss AP, Hargett NA, et al. Clinical comparison of dipivalyl epinephrine and epinephrine in the treatment of glaucoma. Am J Ophthalmol 1979;87(2):196-201
16. Hasslinger C. The use of clonidine in ophthalmologic practice. Buch Augenarzt 1974;63:97-99
17. Araujo SV, Bond JB, Wilson RP, et al. Long term effect of apraclonidine. Br J Ophthalmol 1995;79(12):1098-1101
18. Burke J, Schwartz M. Preclinical evaluation of brimonidine. Surv Ophthalmol 1996;41(Suppl 1):S9-18
19. Cambridge D. UK-14,304, a potent and selective alpha2-agonist for the characterisation of alpha-adrenoceptor subtypes. Eur J Pharmacol 1981;72(4):413-415
20. Matsuo T, Cynader MS. Localization of alpha-2 adrenergic receptors in the human eye. Ophthalmic Res 1992;24(4):213-219
21. Toris CB, Gleason ML, Camras CB, Yablonski ME. Effects of brimonidine on aqueous humor dynamics in human eyes. Arch Ophthalmol 1995;113(12):1514-1517
22. Serle JB, Steidl S, Wang RF, et al. Selective alpha 2-adrenergic agonists B-HT 920 and UK14304-18. Effects on aqueous humor dynamics in monkeys. Arch Ophthalmol 1991;109(8):1158-1162
23. Serle JB. Effect of alpha-2 adrenergic agonists on uveoscleral outflow in rabbits. Invest Ophthalmol Vis Sci 1991;32(Suppl):867
24. Wen R, Cheng T, Li Y, et al. Alpha 2-adrenergic agonists induce basic fibroblast growth factor expression in photoreceptors in vivo and ameliorate light damage. J Neurosci 1996;16(19):5986-5992
25. Yoles E, Wheeler LA, Schwartz M. Alpha2-adrenoreceptor agonists are neuroprotective in a rat model of optic nerve degeneration. Invest Ophthalmol Vis Sci 1999;40(1):65-73
26. Wheeler LA, Lai R, Woldemussie E. From the lab to the clinic: activation of an alpha-2 agonist pathway is neuroprotective in models of retinal and optic nerve injury. Eur J Ophthalmol 1999;9(Suppl 1):S17-21
27. Bylund DB, Chacko DM. Characterization of alpha2 adrenergic receptor subtypes in human ocular tissue homogenates. Invest Ophthalmol Vis Sci 1999;40(10):2299-2306
28. Kent AR, Nussdorf JD, David R, et al. Vitreous concentration of topically applied brimonidine tartrate 0.2%. Ophthalmology 2001;108(4):784-787
29. Ma K, Xu L, Zhang H, et al. Effect of brimonidine on retinal ganglion cell survival in an optic nerve crush model. Am J Ophthalmol 2009;147(2):326-331
30. WoldeMussie E, Ruiz G, Wijono M, Wheeler LA. Neuroprotection of retinal ganglion cells by brimonidine in rats with laser-induced chronic ocular hypertension. Invest Ophthalmol Vis Sci 2001;42(12):2849-2855
31. Krupin T, Liebmann JM, Greenfield DS, et al. The low-pressure glaucoma treatment study (LoGTS) study design and baseline characteristics of enrolled patients. Ophthalmology 2005;112(3):376-385
32. Wheeler L, WoldeMussie E, Lai R. Role of alpha-2 agonists in neuroprotection. Surv Ophthalmol 2003;48(Suppl 1):S47-51
33. Walters TR. Development and use of brimonidine in treating acute and chronic elevations of intraocular pressure: a review of safety, efficacy, dose response, and dosing studies. Surv Ophthalmol 1996;41(Suppl 1):S19-26
34. Chien DS, Homsy JJ, Gluchowski C, Tang-Liu DD. Corneal and conjunctival/scleral penetration of p-aminoclonidine, AGN 190342, and clonidine in rabbit eyes. Curr Eye Res 1990;9(11):1051-1059
35. Salazar M, Shimada K, Patil PN. Iris pigmentation and atropine mydriasis. J Pharmacol Exp Ther 1976;197(1):79-88
36. Acheampong AA, Shackleton M, Tang-Liu DD. Comparative ocular pharmacokinetics of brimonidine after a single dose application to the eyes of albino and pigmented rabbits. Drug Metab Dispos 1995;23(7):708-712
37. Acheampong AA, Chien DS, Lam S, et al. Characterization of brimonidine metabolism with rat, rabbit, dog, monkey and human liver fractions and rabbit liver aldehyde oxidase. Xenobiotica 1996;26(10):1035-1055
38. Acheampong A, Tang-Liu DD. Measurement of brimonidine concentrations in human plasma by a highly sensitive gas chromatography/mass spectrometric assay. J Pharm Biomed Anal 1995;13(8):995-1002
39. Barnebey HS, Robin AL, Zimmerman TJ, et al. The efficacy of brimonidine in decreasing elevations in intraocular pressure after laser trabeculoplasty. Ophthalmology 1993;100(7):1083-1088
40. Derick RJ, Robin AL, Walters TR, et al. Brimonidine tartrate: a one-month dose response study. Ophthalmology 1997;104(1):131-136
41. Katz LJ. Brimonidine tartrate 0.2% twice daily vs timolol 0.5% twice daily: 1-year results in glaucoma patients. Brimonidine study group. Am J Ophthalmol 1999;127(1):20-26
42. Melamed S, David R. Ongoing clinical assessment of the safety profile and efficacy of brimonidine compared with timolol: year-three results. Brimonidine study group II. Clin Ther 2000;22(1):103-111
43. Cantor LB. The evolving pharmacotherapeutic profile of brimonidine, an alpha 2-adrenergic agonist, after four years of continuous use. Expert Opin Pharmacother 2000;1(4):815-834
44. Serle JB. A comparison of the safety and efficacy of twice daily brimonidine 0.2% versus betaxolol 0.25% in subjects with elevated intraocular pressure. The brimonidine study group III. Surv Ophthalmol 1996;41(Suppl 1):S39-47
45. Javitt J, Goldberg I. Comparison of the clinical success rates and quality of life effects of brimonidine tartrate 0.2% and betaxolol 0.25% suspension in patients with open-angle glaucoma and ocular hypertension. Brimonidine outcomes study group II. J Glaucoma 2000;9(5):398-408
46. Fung AT, Reid SE, Jones MP, et al. Meta-analysis of randomised controlled trials comparing latanoprost with brimonidine in the treatment of open-angle glaucoma, ocular hypertension or normal-tension glaucoma. Br J Ophthalmol 2007;91(1):62-68
47. Whitson JT, Henry C, Hughes B, et al. Comparison of the safety and efficacy of dorzolamide 2% and brimonidine 0.2% in patients with glaucoma or ocular hypertension. J Glaucoma 2004;13(2):168-173
48. Stewart W, Sharpe ED, Harbin TS, et al. Brimonidine 0.2% versus dorzolamide 2% each given three times daily to reduce intraocularpressure. Am J Opthalmol 2001;29:723-727
49. Sharpe ED, Day DG, Beischel CJ, et al. Brimonidine purite 0.15% versus dorzolamide 2% each given twice daily to reduce intraocular pressure in subjects with open angle glaucoma or ocular hypertension. Br J Ophthalmol 2004;88(7):953-956
50. van der Valk R, Webers CA, Lumley T, et al. A network meta-analysis combined direct and indirect comparisons between glaucoma drugs to rank effectiveness in lowering intraocular pressure. J Clin Epidemiol 2009;62(12):1279-1283
51. Simmons ST. Efficacy of brimonidine 0.2% and dorzolamide 2% as adjunctive therapy to beta-blockers in adult patients with glaucoma or ocular hypertension. Clin Ther 2001;23(4):604-619
52. Lee DA, Gornbein JA. Effectiveness and safety of brimonidine as adjunctive therapy for patients with elevated intraocular pressure in a large, open-label community trial. J Glaucoma 2001;10(3):220-226
53. Konstas AG, Karabatsas CH, Lallos N, et al. 24-hour intraocular pressures with brimonidine purite versus dorzolamide added to latanoprost in primary open-angle glaucoma subjects. Ophthalmology 2005;112(4):603-608 (Pubitemid 41108860)
54. Bournias TE, Lai J. Brimonidine tartrate 0.15%, dorzolamide hydrochloride 2%, and brinzolamide 1% compared as adjunctive therapy to prostaglandin analogs. Ophthalmology 2009;116(9):1719-1724
55. Thoeschwartzenberg GW, Buys YM. Efficacy of brimonidine 0.2% as adjunctive therapy for patients with glaucoma inadequately controlled with otherwise maximal medical therapy. Ophthalmology 1999 106 8 1616-1620
56. Sherwood MB, Craven ER, Chou C, et al. Twice-daily 0.2% brimonidine-0.5% timolol fixed-combination therapy vs monotherapy with timolol or brimonidine in patients with glaucoma or ocular hypertension: a 12-month randomized trial. Arch Ophthalmol 2006;124(9):1230-1238
57. Nixon DR, Yan DB, Chartrand JP, et al. Three-month, randomized, parallel-group comparison of brimonidine-timolol versus dorzolamide-timolol fixed-combination therapy. Curr Med Res Opin 2009;25(7):1645-1653
58. Hatanaka M, Grigera DE, Barbosa WL, et al. An eight-week, multicentric, randomized, interventional, open-label, Phase 4, parallel comparison of the efficacy and tolerability of the fixed combination of timolol maleate 0.5%/brimonidine tartrate 0.2% versus fixed combination of timolol maleate 0.5%/dorzolamide 2% in patients with elevated intraocular pressure. J Glaucoma 2008;17(8):674-679
59. Schuman JS, Horwitz B, Choplin NT, et al. A 1-year study of brimonidine twice daily in glaucoma and ocular hypertension. A controlled, randomized, multicenter clinical trial. Chronic brimonidine study group. Arch Ophthalmol 1997;115(7):847-852
60. LeBlanc RP. Twelve-month results of an ongoing randomized trial comparing brimonidine tartrate 0.2% and timolol 0.5% given twice daily in patients with glaucoma or ocular hypertension. Brimonidine study group 2. Ophthalmology 1998;105(10):1960-1967
61. Chotani MA, Flavahan S, Mitra S, et al. Silent alpha(2C)-adrenergic receptors enable cold-induced vasoconstriction in cutaneous arteries. Am J Physiol Heart Circ Physiol 2000;278(4):H1075-83
62. Meana JJ, Barturen F, Garcia-Sevilla JA. Alpha 2-adrenoceptors in the brain of suicide victims: increased receptor density associated with major depression. Biol Psychiatry 1992;31(5):471-490
63. Callado LF, Meana JJ, Grijalba B, et al. Selective increase of alpha2A-adrenoceptor agonist binding sites in brains of depressed suicide victims. J Neurochem 1998;70(3):1114-1123
64. Schuman JS. Clinical experience with brimonidine 0.2% and timolol 0.5% in glaucoma and ocular hypertension. Surv Ophthalmol 1996;41(Suppl 1):S27-37
65. Rahman MQ, Montgomery DM, Lazaridou MN. Surveillance of glaucoma medical therapy in a glasgow teaching hospital: 26 years experience. Br J Ophthalmol 2009;93(12):1572-1575
66. Osborne SA, Montgomery DM, Morris D, McKay IC. Alphagan allergy may increase the propensity for multiple eye-drop allergy. Eye 2005;19(2):129-137
67. Butler P, Mannschreck M, Lin S, et al. Clinical experience with the long-term use of 1% apraclonidine. Incidence of allergic reactions. Arch Ophthalmol 1995;113(3):293-296
68. Katz LJ. Twelve-month evaluation of brimonidine-purite versus brimonidine in patients with glaucoma or ocular hypertension. J Glaucoma 2002;11(2):119-126
69. Mundorf T, Williams R, Whitcup S, et al. A 3-month comparison of efficacy and safety of brimonidine-purite 0.15% and brimonidine 0.2% in patients with glaucoma or ocular hypertension. J Ocul Pharmacol Ther 2003;19(1):37-44
70. Cantor LB, Liu CC, Batoosingh AL, Hollander DA. Safety and tolerability of brimonidine purite 0.1% and brimonidine purite 0.15%: a meta-analysis of two Phase 3 studies. Curr Med Res Opin 2009;25(7):1615-1620
71. Craven ER, Walters TR, Williams R, et al. Brimonidine and timolol fixed-combination therapy versus monotherapy: a 3-month randomized trial in patients with glaucoma or ocular hypertension. J Ocul Pharmacol Ther 2005;21(4):337-348
72. Byles DB, Frith P, Salmon JF. Anterior uveitis as a side effect of topical brimonidine. Am J Ophthalmol 2000;130(3):287-291
73. Cates CA, Jeffrey MN. Granulomatous anterior uveitis associated with 0.2% topical brimonidine. Eye 2003;17(5):670-671
74. Hondeghem K, Augustinus B, De Smet MD. Bilateral granulomatous uveitis as a side effect of topical brimonidine: two case reports. Bull Soc Belge Ophtalmol 2009;(311):51-52
75. Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30(2):239-245 (Pubitemid 12149145)
76. Carlsen JO, Zabriskie NA, Kwon YH, et al. Apparent central nervous system depression in infants after the use of topical brimonidine. Am J Ophthalmol 1999;128(2):255-256
77. Korsch E, Grote A, Seybold M, Soditt V. Systemic adverse effects of topical treatment with brimonidine in an infant with secondary glaucoma. Eur J Pediatr 1999;158(8):685
78. Enyedi LB, Freedman SF. Safety and efficacy of brimonidine in children with glaucoma. J Aapos 2001;5(5):281-284
79. Soto-Perez-de-Celis E, Skvirsky DO, Cisneros BG. Unintentional ingestion of brimonidine antiglaucoma drops: a case report and review of the literature. Pediatr Emerg Care 2007;23(9):657-658
80. Vanhaesebrouck S, Cossey V, Cosaert K, et al. Cardiorespiratory depression and hyperglycemia after unintentional ingestion of brimonidine in a neonate. Eur J Ophthalmol 2009;19(4):694-695